Inavolisib

Inavolisib (GDC-0077) is a potent, orally active, and selective PI3Kα inhibitor (IC50=0.038 nM) . Inavolisib exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. Inavolisib is more selective for mutant versus wild-type PI3Kα. Inavolisib can be used for the study of breast cancer[1].

Product Specifications

CAS Number

[2060571-02-8]

Product Name Alternative

GDC-0077; RG6114

UNSPSC

12352005

Hazard Statement

H301, H312, H330, H410

Target

Apoptosis; PI3K

Type

Reference compound

Related Pathways

Apoptosis; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GDC-0077.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@H](C(N)=O)NC1=CC=C(C2=NC(N3[C@H](C(F)F)COC3=O)=CN2CCO4)C4=C1

Molecular Formula

C18H19F2N5O4

Molecular Weight

407.37

Precautions

H301, H312, H330, H410

References & Citations

[1]R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium.